AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00431080
Drug: 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Trial: NCT00955253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02874924
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control
Trial: NCT00996476
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
Trial: NCT01183234
Drug: SPD544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 30mg capsules, single oral dose
Trial: NCT00889629
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
Trial: NCT00853190
Drug: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
RxNorm normalized name: chlorpheniramine polistirex / hydrocodone polistirex Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
Trial: NCT00092352
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003493
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04350593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00677001
Drug: R306465
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04301531
Drug: Treatment for all cases confirmed positive malaria cases with ACTs
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During each mass testing, all confirmed positive cases are treated in both arms.
Trial: NCT00757588
Drug: Placebo + insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
Trial: NCT01954966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
Trial: NCT02078310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Part 2
Trial: NCT04325243
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
Trial: NCT01156792
Drug: GSK2190915 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 100mg QD (AM)
Trial: NCT01156792
Drug: GSK2190915 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2190915 300mg QD (AM)
Trial: NCT01156792
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo BID
Trial: NCT01156792
Drug: FP/SAL 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP/SAL 100/50mcg BID
Trial: NCT00413023
Drug: GW679769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00626301
Drug: LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
Trial: NCT03629288
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
Trial: NCT01505777
Drug: Probiotics (Medirac)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/mosapride 10mg three times a day, P.O. 4week
Trial: NCT01505777
Drug: Probiotics (Medirac)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15/mosapride 10mg three times a day, P.O. 4week
Trial: NCT01505777
Drug: Probiotics (Medirac)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15/mosapride 15mg three times a day, P.O. 4week
Trial: NCT01505777
Drug: Probiotics (Medirac)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30/mosapride 15mg three times a day, P.O. 4week
Trial: NCT04394598
Drug: Dendrobium Huoshanense Granules
RxNorm normalized name: Dendrobium moniliforme whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g tid per day for 5weeks
Trial: NCT00577577
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
Trial: NCT03032432
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection to improve rotator cuff tendinosis pain and functional score
Trial: NCT04394598
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625mg/m2 bid Monday-Friday per week
Trial: NCT06485453
Drug: Botox 200 UNT Injection
RxNorm normalized name: Botox 200 UNT Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
Trial: NCT00073866
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00496769
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 81-324 mg, once daily, up to 156 weeks
Trial: NCT00230035
Drug: Growth colony stimulating factor (G-CSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230035
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230035
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00230035
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04643132
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Trial: NCT06135181
Drug: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
Trial: NCT06135181
Drug: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
Trial: NCT06135181
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride by intravenous injection (at 2 mL/s)
Trial: NCT03723252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo po qd
Trial: NCT03622762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules, 400 mg twice daily fasting
Trial: NCT00454961
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00260156
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00223717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Po or patch. Single dose.
Trial: NCT00223717
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50-100 mg po. Single dose.
Trial: NCT01474395
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Trial: NCT04532554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline injection with the same amount
Trial: NCT01474395
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Trial: NCT01980953
Drug: GDC-0032 Phase III Tablet
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
Trial: NCT03478423
Drug: Codeine
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Trial: NCT04737187
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
Trial: NCT00760773
Drug: Lacidophil (experimental standard dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
Trial: NCT00760773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
Trial: NCT02273401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02455154
Drug: Zhongyaofufang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine for patients with Osteoporosis
Trial: NCT02455154
Drug: Xianlinggubao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine for patients with Osteoporosis
Trial: NCT02772419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration
Trial: NCT00785083
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00785083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02022358
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (12 g/m2 x 1, intravenously)
Trial: NCT04068766
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Trial: NCT02110719
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02110719
Drug: oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01082029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
Trial: NCT03541174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT04556292
Drug: SC10914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC10914 400mg tid
Trial: NCT00903604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 10-minutes infusions of isotonic saline solution
Trial: NCT01827475
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single dose
Trial: NCT01827475
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01827475
Drug: Ibuprofen-acetaminophen combination
RxNorm normalized name: ibuprofen, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT00495053
Drug: hMaxi-K
RxNorm normalized name: Effer-K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
Trial: NCT00134745
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
Trial: NCT02576301
Drug: Phase 1 - OXi4503
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Determination of MTD of OXi4503
Trial: NCT04027192
Drug: BAY2328065 LSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/mL LSF (liquid service formulation), orally
Trial: NCT04027192
Drug: BAY2328065 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, orally
Trial: NCT04027192
Drug: Placebo LSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo LSF, orally
Trial: NCT04027192
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tablet, orally
Trial: NCT00416832
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00416832
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04552483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
Trial: NCT00650351
Drug: Cipro® XR Tablets 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg, single dose fed
Trial: NCT00641329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT02351934
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
Trial: NCT00368251
Drug: BRV 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use
Trial: NCT00368251
Drug: BRV 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use
Trial: NCT00368251
Drug: BRV 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Trial: NCT03740464
Drug: long-acting granulocyte colony stimulating factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
Trial: NCT03210740
Drug: AM001 Cream, 7.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Cream
Trial: NCT03210740
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placeo
Trial: NCT03350386
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration
Trial: NCT03350386
Drug: Oxaprozin
RxNorm normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repeated administration
Trial: NCT02121301
Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eyedrops
Trial: NCT00930020
Drug: Minocycline (Borymycin)
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dose, 200 mg once a day for 5 days
Trial: NCT00930020
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched placebo (cornstarch) once a day for 5 days
Trial: NCT00183339
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
Trial: NCT02121301
Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eyedrops
Trial: NCT02121301
Drug: Placebo (Vehicle) opthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eyedrops
Trial: NCT03350477
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT03147092
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypertensive subjects
Trial: NCT00183339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
Trial: NCT00526474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching tablet daily for at least 1 year
Trial: NCT02891590
Drug: DTRMWXHS-12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02809027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579499
Drug: fixed high potent statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
Trial: NCT02579499
Drug: targeted LDL-C goal statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)
Trial: NCT04224350
Drug: TacroBell SR cap.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.